Serina Therapeutics Inc (SER) Stock Price, Quote & News

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which...

Industry: Biotechnology

Sector: Healthcare

Phone: 256 327 9630

Website: serinatherapeutics.com

Address:

601 Genome Way, Suite 2001, Huntsville, United States

BullsEyePick Oct. 2 at 4:56 AM

Looking for the next Monster runner?🚨🚨 Make sure you have ticker IVDA on ur watch. IVDA is Truly a gem of a ticker, known for big runs and perfect for a market like this where this can go on a massive rally of 400-500%+. IVDA has everything going for it, news/approved crypto treasury/Ai /Drone and most important of all it's a low float ticker. Be early bulls, because it will take off fast!!! $OPEN $YDES $SER $SEED

1 · Reply

titto25 Oct. 1 at 10:37 AM

$SER 7 imo

0 · Reply

BullsEyePick Sep. 20 at 8:02 PM

Ticker BOXL has the same ingredients as past parabolic runners — but it’s still cheap.💎 Top watch next week. ✅ Zero borrow ✅ No dilution ✅ $30+ valuation case ✅ Next leg could be wild. Also watching. $RMCF $YDES $SER $VNRX

2 · Reply

titto25 Sep. 12 at 7:26 PM

$SER worth much more maybe 7 or 8 imo

0 · Reply

NVDAMillionaire Sep. 11 at 6:12 AM

$SER Excellent article that nails exactly where SER stands right now. So if you want to update your SER knowledge or get acquainted with SER, this is a must read. https://beyondspx.com/quote/SER/analysis/serina-therapeutics-unlocking-neurological-potential-with-poz-despite-liquidity-headwinds-nyse-american-ser

0 · Reply

jheerdink Sep. 10 at 1:38 PM

$SER Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that it has entered into an agreement to access up to $20 million in financing led by Serina Board Director Greg Bailey, MD. The financing also includes the issuance of warrants which, if fully issued and exercised, could result in additional proceeds of up to $20 million. https://finance.yahoo.com/news/serina-therapeutics-secures-20-million-192000794.html

0 · Reply

BigSqueezeComing Sep. 9 at 8:03 PM

$SER ah runner Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease By Serina Therapeutics, Inc. | September 09, 2025, 3:20 PM

0 · Reply

simplifocused Sep. 9 at 7:55 PM

$SER HALTED FOLLOWING A STRONG NEWS Serina Therapeutics Gets Up to $20 Million to Advance Parkinson's Treatment CAN IT FOLLOW $ORBS OR $QMMM? JOURNEY? NFA

0 · Reply

DekDougan Sep. 9 at 7:51 PM

$SER $20M in non-dilutive funding led by largest shareholder. Huge news

1 · Reply

wsb_kenny Sep. 9 at 7:25 PM

$SER Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease. $15 soon.

1 · Reply

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Sep 8, 2025, 6:00 AM EDT - 26 days ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 4:15 PM EDT - 5 weeks ago

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Aug 11, 2025, 4:30 PM EDT - 7 weeks ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Jul 29, 2025, 6:44 AM EDT - 2 months ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 28, 2025, 6:00 AM EDT - 2 months ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 10, 2025, 4:10 PM EDT - 3 months ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 1, 2025, 4:15 PM EDT - 3 months ago

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jun 23, 2025, 7:24 PM EDT - 3 months ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 17, 2025, 8:30 PM EDT - 3 months ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 3 months ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 9, 2025, 4:05 PM EDT - 4 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

May 22, 2025, 4:50 PM EDT - 4 months ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 14, 2025, 3:15 PM EDT - 5 months ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 8, 2025, 4:23 PM EDT - 5 months ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Apr 29, 2025, 6:00 AM EDT - 5 months ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 15, 2025, 6:30 AM EDT - 6 months ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 8, 2025, 4:30 PM EDT - 6 months ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 7, 2025, 6:30 AM EDT - 6 months ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:30 PM EDT - 6 months ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 6:30 AM EDT - 6 months ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Feb 12, 2025, 4:15 PM EST - 8 months ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 3, 2025, 4:30 PM EST - 8 months ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Jan 15, 2025, 4:05 PM EST - 9 months ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 14, 2025, 5:25 PM EST - 9 months ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Dec 16, 2024, 6:00 AM EST - 10 months ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 11, 2024, 6:05 AM EST - 10 months ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 2, 2024, 5:22 PM EST - 10 months ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Nov 12, 2024, 5:00 PM EST - 11 months ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Sep 4, 2024, 6:42 PM EDT - 1 year ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 18, 2024, 5:00 PM EDT - 1 year ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

May 14, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

Mar 26, 2024, 5:04 PM EDT - 1 year ago

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

Mar 22, 2024, 5:27 PM EDT - 1 year ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Feb 27, 2024, 3:19 PM EST - 1 year ago

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

Nov 14, 2023, 4:05 PM EST - 2 years ago

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Aug 30, 2023, 7:00 AM EDT - 2 years ago

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

Aug 14, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

Jul 24, 2023, 6:28 PM EDT - 2 years ago

AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

Jul 21, 2023, 5:32 PM EDT - 2 years ago

AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock

May 23, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Announces Appeal of NYSE American Determination

May 17, 2023, 5:31 PM EDT - 2 years ago

CORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)

May 17, 2023, 4:34 PM EDT - 2 years ago

NYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting Proceedings

May 12, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports First Quarter 2023 Financial Results

Apr 26, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

BullsEyePick Oct. 2 at 4:56 AM

1 · Reply

titto25 Oct. 1 at 10:37 AM

$SER 7 imo

0 · Reply

BullsEyePick Sep. 20 at 8:02 PM

2 · Reply

titto25 Sep. 12 at 7:26 PM

$SER worth much more maybe 7 or 8 imo

0 · Reply

NVDAMillionaire Sep. 11 at 6:12 AM

0 · Reply

jheerdink Sep. 10 at 1:38 PM

0 · Reply

BigSqueezeComing Sep. 9 at 8:03 PM

$SER ah runner Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease By Serina Therapeutics, Inc. | September 09, 2025, 3:20 PM

0 · Reply

simplifocused Sep. 9 at 7:55 PM

$SER HALTED FOLLOWING A STRONG NEWS Serina Therapeutics Gets Up to $20 Million to Advance Parkinson's Treatment CAN IT FOLLOW $ORBS OR $QMMM? JOURNEY? NFA

0 · Reply

DekDougan Sep. 9 at 7:51 PM

$SER $20M in non-dilutive funding led by largest shareholder. Huge news

1 · Reply

wsb_kenny Sep. 9 at 7:25 PM

$SER Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease. $15 soon.

1 · Reply

perfectson Sep. 9 at 7:16 PM

$SER halted - pending news

0 · Reply

titto25 Sep. 5 at 6:29 PM

$SER look at the chart it will be above 6 .5 sooner than later

0 · Reply

titto25 Sep. 4 at 9:51 AM

$SER

0 · Reply

Bullliissh Sep. 3 at 6:57 PM

$SER

0 · Reply

StockBroker101 Sep. 2 at 2:35 PM

$NVDA This is going to boom up $SER My new favorite stock THIS STOCK IS READY TO EXPLODE UP if your looking for some massive gains today $SER to the moon opportunity waiting for you . Your welcome!!!

0 · Reply

titto25 Aug. 29 at 7:11 PM

$SER

0 · Reply

StockBroker101 Aug. 29 at 2:14 PM

$OPEN $OPAD $SER $SER dont miss out on this one

0 · Reply

StockBroker101 Aug. 29 at 2:07 PM

$PMI Here we go baby! $SER check this one out

0 · Reply

BioTechHealthX Aug. 29 at 1:57 AM

$SER Analysts see Serina stock surging as its unique POZ technology delivers long-acting therapies for neurological diseases with huge unmet need. https://biotechhealthx.com/biotech-news/wall-street-predicts-130-upside-for-serina-therapeutics-ser/

0 · Reply

wsb_kenny Aug. 28 at 7:13 PM

$SER it's time for run back to $8.8

1 · Reply

titto25 Aug. 28 at 6:57 PM

$SER volume low need wome volume to move up

0 · Reply

JarvisFlow Aug. 28 at 11:30 AM

HC Wainwright & Co. updates rating for Serina Therapeutics ( $SER ) to Buy, target set at 15.

0 · Reply

Market Cap	55.17M
Revenue (ttm)	60,000.00
Net Income (ttm)	-11.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18,566.67%
Debt to Equity Ratio	0.00

Volume	18,500
Avg Vol	150,520
Day's Range	N/A - N/A
Shares Out	10.54M
Stochastic %K	58%
Beta	0.75
Analysts	Strong Sell
Price Target	$13.00